Chromosome Aberrations (Chromosome Abnormalities)

Abnormal number or structure of chromosomes. Many chromosome aberrations, but not all, are the cause of CHROMOSOME DISORDERS.
Also Known As:
Chromosome Abnormalities; Chromosomal Abnormalities; Abnormalities, Chromosome; Chromosomal Aberrations; Chromosomal Abnormality; Chromosome Aberration; Abnormalities, Autosome; Abnormalities, Chromosomal; Cytogenetic Abnormalities; Aberration, Chromosomal; Aberration, Chromosome; Aberration, Cytogenetic; Aberrations, Chromosomal; Aberrations, Chromosome; Aberrations, Cytogenetic; Abnormal Karyotypes; Abnormalities, Cytogenetic; Abnormality, Autosome; Abnormality, Chromosomal; Abnormality, Chromosome; Abnormality, Cytogenetic; Autosome Abnormality; Chromosomal Aberration; Chromosome Abnormality; Cytogenetic Aberration; Cytogenetic Abnormality; Karyotypes, Abnormal; Abnormal Karyotype; Autosome Abnormalities; Cytogenetic Aberrations; Karyotype, Abnormal
Networked: 9172 relevant articles (218 outcomes, 923 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Leukemia
2. Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
3. Myelodysplastic Syndromes (Myelodysplastic Syndrome)
4. Neoplasms (Cancer)
5. Philadelphia Chromosome


1. Bolzán, Alejandro D: 19 articles (12/2015 - 06/2002)
2. Bianchi, Martha S: 16 articles (01/2013 - 06/2002)
3. Xu, Wei: 16 articles (10/2012 - 10/2006)
4. Afzal, Mohammad: 16 articles (09/2010 - 07/2002)
5. Barlogie, Bart: 15 articles (06/2013 - 10/2002)
6. Li, Jian-Yong: 15 articles (06/2012 - 10/2006)
7. Kaina, Bernd: 14 articles (07/2015 - 01/2002)
8. Natarajan, A T: 14 articles (08/2013 - 06/2000)
9. Durante, M: 14 articles (08/2013 - 06/2000)
10. Nicolaides, K H: 14 articles (06/2011 - 05/2000)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Chromosome Aberrations:
1. DNA (Deoxyribonucleic Acid)IBA
2. lenalidomide (CC 5013)FDA Link
3. Cyclophosphamide (Cytoxan)FDA LinkGeneric
4. Cytarabine (Cytosar-U)FDA LinkGeneric
5. Ascorbic Acid (Vitamin C)FDA LinkGeneric
6. imatinib (Gleevec)FDA Link
7. 9,10-Dimethyl-1,2-benzanthracene (DMBA)IBA
8. Biological Markers (Surrogate Marker)IBA
9. CatalaseIBA
10. Benzene (Benzole)IBA

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
08/01/2013 - "Diagnostic clonal chromosomal abnormalities provide important prognostic information and are among the most important factors in predicting initial response to chemotherapy, duration of remission and overall survival.  This study analyzed chromosomal abnormalities in bone marrow aspirates of 50 children diagnosed with acute myeloid leuckemia (AML).  The culture success rate was 94%, clonal chromosomal abnormalities constituted 62% and recurrent chromosomal abnormalities were 56%. "
01/01/2005 - "The chemotherapy complete remission rate was 68.8% in patients with only Ph+ versus 28.6% in those with additional chromosome abnormalities. "
12/01/1998 - "Cytogenetic analysis revealed a single abnormal karyotype of 47,XY,+6,add(15)(q22) which was successfully detected by fluorescence in situ hybridization (FISH) with the probe mapping at the alpha-satellite region of chromosome 6. Although the patient was treated with several chemotherapy regimens, he could not achieve complete remission and he died of progressive disease 11 months after admission. "
05/01/1997 - "Among 80 patients treated with chemotherapy, the presence of a secondary chromosome abnormality was associated with longer complete remission (CR) duration (median, 29.9 v 15.7 months; P = .03) and longer event-free survival (EFS) duration (median, 17.0 v 12.2 months; P = .03). "
11/01/2015 - "We report on an APL patient with iso(17q) as the sole cytogenetic aberration and a cryptic PML-RARA transcript, who was treated with ATRA and ATO after failure of chemotherapy and achieved complete remission. "
2. Transplants (Transplant)
05/01/2008 - "TT2's major advance vis-à-vis TT1 pertained to the subgroup without cytogenetic abnormalities (CA), supporting the role of post-transplant consolidation therapy, whereas the improved survival of the CA subgroup on the experimental versus control arm of TT2 attests to the role of THAL in this setting. "
02/01/2008 - "It is concluded that 3q21q26 aberration commonly combined with chromosome aberration 7/7q-, for these patients the efficacy of chemical therapy is poor, the efficacy of bone marrow transplant is too poor, these patients with inv(3q) and t(3; 3) aberrations have poor prognosis and short overall survival."
06/01/2007 - "In the context of Total Therapy 2, a tandem transplant trial for newly diagnosed myeloma, comprehensive information was available in 220 patients on standard prognostic factors (SPF), magnetic resonance imaging (MRI)-defined focal lesions, cytogenetic abnormalities (CA), fluorescence-in-situ-hybridisation (FISH)-derived amplification of chromosome 1q21 (amp1q21) and deletion of 13q14, as well as gene expression profiling (GEP). "
06/01/2000 - "Retrospective cytogenetic and FISH studies of samples obtained after six cycles of FAC/FEC and before transplant demonstrated no chromosomal abnormalities in any of the five patients with post-ASCT karyotypic changes. "
10/15/1998 - "At this time, eight months after transplant, repeat study of his bone marrow revealed the majority of metaphases had structural and numerical chromosome abnormalities similar to the small clone in the earlier study, including der(5)t(5;9)ins(5;7), but with two normal 7s. "
3. Transplantation (Transplant Recipients)
4. Aftercare (After-Treatment)
5. Radiotherapy